Project Grant R41DA064241
Award Date 7/1/26
Completion Date 6/30/27
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- Federal Project Grant Award Summary Aruna Bio, Inc. received a $799,994 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded August 15, 2025, with completion targeted for July 31, 2026. The award supports development of neural exosome therapeutics to treat brain injuries resulting from non-fatal opioid-associated overdose (NFOO)-induced hypoxia. While current interventions such as naloxone effectively reduce...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $577,531 Project Grant to Washington University (awarded March 15, 2026; completion November 30, 2030) to generate the first single-nucleus paired RNA-sequencing and ATAC-sequencing (multiome) data from key brainstem respiratory control regions in fentanyl overdose decedents. The research will examine tissue samples from 40 fentanyl overdose...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Children's Hospital of Philadelphia Research Institute a $1.068 million Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) for a five-year research initiative beginning September 1, 2025, and concluding May 31, 2030. This award funds investigation into the lifespan effects of prenatal and perinatal opioid exposure on the brain's metabolic-epigenetic axis. The project...
- Federal Project Grant Award Summary Praeventix LLC received a $355,190 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded June 1, 2026, with an ultimate completion date of May 31, 2027. The grant funds in vivo characterization studies of 5-HT7 modulators, specifically the lead compound PRA078, in rat models of opioid use disorder (OUD). The research evaluates how antagonism of the 5-HT7 receptor regulates...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Icahn School of Medicine at Mount Sinai a $2.352 million Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) on February 15, 2026, with completion targeted for January 31, 2030. This award funds single-molecule functional validation research examining neurogenomic alterations in opioid-exposed human immunodeficiency virus (HIV) brain tissue. The primary deliverables include...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $100,228 Project Grant to Icahn School of Medicine at Mount Sinai on October 8, 2026, with a completion date of June 30, 2028. This award funds research investigating the role of a novel cortical circuit in opioid reward mechanisms. The project addresses the significant public health challenge of opioid use disorder (OUD) and...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded UC San Diego a $197,500 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) effective September 1, 2025, through August 31, 2027. The award supports development and validation of an in vivo Massively Parallel Reporter Assay (MPRA) methodology to characterize the functional role of cis-regulatory elements and genetic variants associated with substance use disorders. Specifically, the...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Johns Hopkins University a Project Grant totaling $466,363 under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on allosteric crosstalk among pain receptors. The project, which commenced June 1, 2026 and extends through April 30, 2031, focuses on elucidating the molecular mechanisms by which endogenous neuromodulators—specifically endocannabinoids and...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the Lieber Institute for Brain Development a Project Grant of $1.855 million under the Drug Use and Addiction Research Programs (CFDA 93.279), effective March 1, 2026 through February 28, 2029. The grant funds development of three-dimensional cellular-resolution spatio-molecular maps of the human nucleus accumbens (NAC), a critical brain region implicated in reward signaling and substance use disorders. The primary...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Tufts University School of Medicine a Project Grant totaling $386,500 under the Drug Use and Addiction Research Programs (CFDA 93.279) on September 15, 2025, with a completion date of August 31, 2027. This R21 research grant supports basic neuroscience research investigating the relationship between fentanyl overdose (OD), anhedonia (loss of pleasure/reward motivation), and relapse risk in opioid use disorder...